Percutaneous ethanol injection therapy in the treatment of hepatocarcinoma--results obtained from a series of 88 cases.
OBJECTIVE
To assess the efficacy of Percutaneous Ethanol Injection Therapy (PEIT) for the treatment of hepatocarcinoma in a series of Romanian patients, and to compare it with previous studies.


METHODS
We retrospectively evaluated 88 patients with liver cirrhosis (LC) and hepatocellular carcinoma (HCC) treated by PEIT. Multiple sessions of PEIT were performed to treat a single nodule of 2-10 cm in diameter. The Child-Pugh classification was used for evaluating the severity of LC and the Okuda and Barcelona scores for HCC. The efficacy of PEIT was assessed by CT or MRI one month after the therapy. The patients' survival after PEIT was calculated starting from the first PEIT procedure until the moment of death or the end of study (2000-2005). We analyzed the main factors which influenced the survival of the treated patients.


RESULTS
The global survival was 38.07+/-3.97 months, longer in patients with Child-Pugh A class, than in Child-Pugh B class (Log Rank 0.04). Patients with HCC less than 3 cm in diameter survived significantly longer than patients with tumors larger than 5 cm (Log Rank 0.007). Also, survival was better in the Barcelona A stage than in the Barcelona B and C stages (Log Rank 0.002) and in patients with alpha-fetoprotein less than 200 ng/l (Log Rank 0.002).


CONCLUSIONS
The main factors which influenced the survival of patients treated by PEIT were: the size of the HCC, the Child-Pugh class, the Barcelona stage and the level of alpha-fetoprotein at the time of initiation of therapy.
Danila
Mirela
M
Department of Gastroenterology and Hepatology, University of Medicine and Pharmacy Timişoara, Martir Petru Dămăşneanu Str. 73 300351 Timişoara, Romania. mireladanila@gmail.com
Sporea
Ioan
I
Sirli
Roxana
R
Popescu
Alina
A
D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000401:mortality; D000431:Ethanol / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D007267:Injections; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015996:Survival Rate; D000509:alpha-Fetoproteins / Q000032:analysis
D000509:alpha-Fetoproteins; D000431:Ethanol